Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Trends in the Management of Non-Melanoma Skin Cancers

February 15, 2019
By Naveed Saleh, MD, MS
Article

A recent review article highlighted developments in the treatment of non-melanoma skin cancers, from new chemoprevention agents to telemedicine.

Various trends in the prevention and treatment of non-melanoma skin cancer-from new chemoprevention agents to the role of telemedicine-were highlighted in a recent review published in the journal Current Opinion in Pharmacology.

“Many of these trends have the potential to make a big impact,” said Mackenzie Wehner, MD, MPhil, a clinical instructor and post-doctoral research fellow in dermatology at the University of Pennsylvania, in an interview with Cancer Network. “Improving access to care, treatment of actinic keratoses, sun protection and chemoprevention in high-risk groups, and newer therapies for advanced cancers are all poised to make a big difference.”

Among the most important trends noted in the review are several new or emerging therapies, according to Wehner. “I will be eagerly watching to see new data on medicines for prevention, particularly the over-the-counter nicotinamide, which has shown very promising results in an Australian trial for patients with multiple keratinocyte carcinomas,” she said.

Wehner also noted the value of vismodegib, checkpoint inhibitors, and programmed cell death 1 (PD-1) blockade, which are transforming the treatment of advanced skin cancers. Specifically, vismodegib or radiotherapy is used to treat inoperable basal cell carcinoma. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, have proven effective in the treatment of inoperable and/or metastatic squamous cell carcinoma. PD-1 blockade with cemiplimab has been demonstrated to be effective in advanced cutaneous squamous cell carcinoma, with clinical response in about 50% of patients.

With regard to prevention, the review highlighted the failure to impact rural populations using conventional media, such as special-interest magazines promoting sun protection. The researchers noted that effective health communication alternatives in this population may include teledermatology and teledermoscopy, as well as smart phone apps or text messages.

Wehner stressed the dangers of indoor tanning, another trend not mentioned in the review. “I also think that limits and bans on indoor tanning will have a big impact, though it may be many decades before we see those results.”

Jerry D. Brewer, MD, MS, a professor of dermatology at the Mayo Clinic in Rochester, Minnesota, said the article does a good job of spreading important messages about non-melanoma skin cancer.

“The field of dermatology is very aware of the trends, and this paper does not have a paradigm-shifting effect on those who are already skin cancer experts. However, it may have an impact on other fields of medicine that are less aware of the health implications associated with non-melanoma skin cancer,” Brewer said in a separate interview with Cancer Network. “The most important thing is that, even though these non-melanoma skin cancers have been traditionally thought of as not a big deal, they can be life threatening and/or debilitating if not treated appropriately.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
Related Content

Samples were analyzed using 40-GEP clinical testing standard operating procedures. The trial end points were LRFS and MFS.

DecisionDx-SCC Predicts Recurrence, Guides Imaging in Squamous Cell Carcinoma

Tim Cortese
August 28th 2025
Article

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
August 28th 2025
Podcast

It was reported that though the treatment did not demonstrate statistical significance, it did yield a clinically meaningful improvement in PFS.

Novel Cancer Vaccine Combo Therapy Numerically Improves PFS in Melanoma

Tim Cortese
August 28th 2025
Article

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
August 28th 2025
Podcast

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

ONCOLOGY Staff
August 28th 2025
Article

Credit: Northwell Health

Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion

Ariana Pelosci
August 28th 2025
Article
Related Content

Samples were analyzed using 40-GEP clinical testing standard operating procedures. The trial end points were LRFS and MFS.

DecisionDx-SCC Predicts Recurrence, Guides Imaging in Squamous Cell Carcinoma

Tim Cortese
August 28th 2025
Article

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

John M. Kirkwood, MD
August 28th 2025
Podcast

It was reported that though the treatment did not demonstrate statistical significance, it did yield a clinically meaningful improvement in PFS.

Novel Cancer Vaccine Combo Therapy Numerically Improves PFS in Melanoma

Tim Cortese
August 28th 2025
Article

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

Matthew Fowler;Emily Hoffman Smith, MD
August 28th 2025
Podcast

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

3 Things You Should Know About Managing Advanced Melanoma With Oncolytic Viral Immunotherapies

ONCOLOGY Staff
August 28th 2025
Article

Credit: Northwell Health

Singh to Advance Northwell’s Skin Cancer Program With Surgical Director Promotion

Ariana Pelosci
August 28th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.